4 completed, 2 terminated, 2 unknown, 1 not yet recruiting. 4 Phase 2, 1 Not applicable, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 2, Terminated 1, Unknown 1 |
| Not applicable | 1 | Unknown 1 |
| Phase 1 | 1 | Unknown 1 |
| Phase 3 | 1 | Terminated 1 |
Follow Hematopoietic Neoplasm: new trials by email Literature Review of Hematopoietic Neoplasm trials Research Report on Hematopoietic Neoplasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Wearable Data for Personalized Prognostication in Cancer: A Registry Protocol Non-Interventional Study - Hematopoietic Neoplasm, Malignant Solid Neoplasm | Not yet recruiting | City of Hope Medical Center | 1200 | 2026-12-01 | 2026-07-08 | |
| Wearable Activity Tracking to Curb Hospitalizations Fitbit, Apple HealthKit-based devices - Hematopoietic Neoplasm, Malignant Solid Neoplasm | Recruiting | University of California, San Francisco | 260 | 2025-04-07 | 2026-09-23 | |
| Addressing Financial Hardship in Adolescent and Young Adult Cancer Survivors CHAT Core Functions, LIFT Core Functions, Member-Checking Process - Hematopoietic Neoplasm, Malignant Solid Neoplasm | Completed | Wake Forest University Health Sciences | 16 | 2024-11-04 | 2026-03-03 | |
| Effectiveness of Extraoral Photobiomodulation in Management of Oral Adverse Effects in Patients Undergoing HSCT Photobiomodulation therapy (intraoral), Photobiomodulation therapy (extraoral) - Oral Mucositis, Hematopoietic Neoplasm | Not applicable | Unknown | Federal University of Rio Grande do Sul | 42 | 2023-01-13 | 2023-03-08 |
| GVHD Prophylaxis With Methotrexate in Haploidentical HCT Using Posttransplant Cyclophosphamide Methotrexate Injectable Solution - Graft Vs Host Disease, Hematopoietic Neoplasm | Phase 1 / Phase 2 | Unknown | University of Sao Paulo General Hospital | 47 | 2020-10-07 | 2021-09-14 |
| UF-BMT-HSCT-001: A Non-Interventional Study Evaluating Diet in HSCT Survivors Dietary intake -Food Frequency Questionnaire, Receptivity to Participating in Diet Interventions - Hematopoietic Neoplasm | Completed | University of Florida | 103 | 2017-12-14 | 2019-09-17 | |
| Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib SAR302503 - Hematopoietic Neoplasm | Phase 2 | Terminated | Bristol-Myers Squibb | 97 | 2012-04-30 | 2026-07-16 |
| Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis SAR302503, Placebo - Hematopoietic Neoplasm | Phase 3 | Terminated | Bristol-Myers Squibb | 289 | 2011-12-31 | 2026-08-11 |
| Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia SAR302503 - Hematopoietic Neoplasm | Phase 2 | Completed | Bristol-Myers Squibb | 81 | 2011-10-01 | 2025-03-05 |
| Phase 2 Study of SAR302503 in Patients With Myelofibrosis SAR302503 - Hematopoietic Neoplasm | Phase 2 | Completed | Bristol-Myers Squibb | 30 | 2011-08-01 | 2025-03-05 |
Hematologic Neoplasms (10) · Graft vs Host Disease (1) · Stomatitis (1) · Xerostomia (1)
Hematologic Diseases (10) · Hemic and Lymphatic Diseases (10) · Neoplasms (10) · Neoplasms by Site (10) · Immune System Diseases (1) · Mouth Diseases (1) · Salivary Gland Diseases (1) · Stomatognathic Diseases (1)
fedratinib (4) · Low-Level Light Therapy (1)
Bristol-Myers Squibb (4) · City of Hope Medical Center (1) · Federal University of Rio Grande do Sul (1) · University of California, San Francisco (1) · University of Florida (1) · University of Sao Paulo General Hospital (1) · Wake Forest University Health Sciences (1)
United States (7) · Brazil (3) · Canada (3) · France (3) · Germany (3) · Italy (3) · Spain (3) · United Kingdom (3) · Australia (2) · Austria (2) · Belgium (2) · South Korea (2) · Hungary (1) · Ireland (1) · Israel (1)
Giancarlo Fatobene, MD (1) · John Salsman, PhD (1) · Julian Hong, MD, MS (1) · Lee Jones (1) · Manoela D Martins, PhD (1) · Nosha Farhadfar, MD (1)
R01CA277782 (1), R01CA282653 (1)